Abiopharma

🔍 WENDLER DANIEL (Executive)

Company: FLEX LTD. (FLEX)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Acquired 9,716 shares of Ordinary Shares (Direct)
  Date: 2026-05-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 37,335.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 312 shares of Ordinary Shares at $138.5957 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 37,023.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 335 shares of Ordinary Shares at $139.7618 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 36,688.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 414 shares of Ordinary Shares at $140.6742 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 36,274.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 234 shares of Ordinary Shares at $141.837 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 36,040.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Sold 1,081 shares of Ordinary Shares at $142.9077 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 34,959.00 | transaction_form_type: 4 | Footnotes: F2, F7
• Sold 996 shares of Ordinary Shares at $143.827 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 33,963.00 | transaction_form_type: 4 | Footnotes: F2, F8
• Sold 447 shares of Ordinary Shares at $144.4416 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 33,516.00 | transaction_form_type: 4 | Footnotes: F2, F9, F10

Footnotes:

• F1: On June 14, 2023, the Reporting Person was awarded performance-based restricted share units ("PSUs") within a preset range, with the actual number contingent upon the achievement of a certain performance criterion with respect to the three-year performance period ending on March 31, 2026. The Issuer certified the achievement of the performance criterion, and the PSUs fully vested, on May 8, 2026, and were subject to applicable taxes upon delivery.
• F2: The sales reported in this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs.
• F3: Price reflects weighted average sales price; actual sales prices ranged from $138.185 to $139.144. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F4: Price reflects weighted average sales price; actual sales prices ranged from $139.198 to $140.179. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F5: Price reflects weighted average sales price; actual sales prices ranged from $140.25 to $141.115. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F6: Price reflects weighted average sales price; actual sales prices ranged from $141.281 to $142.218. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F7: Price reflects weighted average sales price; actual sales prices ranged from $142.299 to $143.294. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F8: Price reflects weighted average sales price; actual sales prices ranged from $143.308 to $144.305. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F9: Price reflects weighted average sales price; actual sales prices ranged from $144.32 to $144.765. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F10: Includes the following: (1) 4,484 unvested restricted share units ("RSUs"), which will vest in two equal annual installments beginning on June 12, 2026; (2) 5,164 unvested RSUs, which will vest in three equal annual installments beginning on June 12, 2026; and (3) 3,238 unvested RSUs, which will vest on June 14, 2026.
• F11: Each unvested RSU represents a contingent right to receive one unrestricted, fully transferable share for each vested RSU which has not been previously forfeited.